Genocea Biosciences Inc

(No Reviews)
100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA

Genocea Biosciences Inc is located in Middlesex County of Massachusetts state. On the street of Acorn Park Drive and street number is 100. To communicate or ask something with the place, the Phone number is (617) 876-8191. You can get more information from their website.
The coordinates that you can use in navigation applications to get to find Genocea Biosciences Inc quickly are 42.3979265 ,-71.1496458

Contact and Address

Address: 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA
Postal code: 02140
Phone: (617) 876-8191
Website: https://www.genocea.com/

Opening Hours:

Monday:9:00 AM – 5:00 PM
Tuesday:9:00 AM – 5:00 PM
Wednesday:9:00 AM – 5:00 PM
Thursday:9:00 AM – 5:00 PM
Friday:9:00 AM – 5:00 PM
Saturday:Closed
Sunday:Closed

Location & routing

Get Directions

Reviews

There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Genocea Biosciences Inc, use the form below and your opinion, advice or comment will appear in this space.

Write a Review

Photos of Genocea Biosciences Inc

Genocea Biosciences Inc | 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA | Phone: (617) 876-8191
Genocea Biosciences Inc | 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA | Phone: (617) 876-8191
Genocea Biosciences Inc | 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA | Phone: (617) 876-8191

Genocea Biosciences Inc On the Web

Genocea - Official Site

Genocea's mission is to help conquer cancer through targeted vaccines and immunotherapies. Using our revolutionary ATLAS™ platform to identify true T cell antigens, we are creating new lifelines for cancer patients by listening to and learning from the immune system.


Contact — Genocea

For Business Development Inquiries Sudhir Rao business.development@genocea.com. For Media and Investor Inquiries Jennifer LaVin 617.715.6687 IR@genocea.com


Genocea Biosciences, Inc.: Private Company Information ...

617-876-8191. Fax: 617-876-8192. www.genocea.com. ... Genocea Biosciences, Inc. announced the dosing of the first patients in its Phase 1/2a clinical trial testing the safety, immunogenicity, and ...


Genocea Biosciences, Inc. - MassBio

Genocea Biosciences, Inc. was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. Contact 617-876-8191 Company Website @GenoceaBio


Genocea Biosciences, Inc. 8-K Sep. 25, 2017 4:57 PM | Seeking ...

Registrant's telephone number, including area code: (617) 876-8191 Not applicable ... CAMBRIDGE, Mass., September 25, 2017 - Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company ...


GNCA:NASDAQ CM Stock Quote - Genocea Biosciences Inc ...

Genocea Biosciences, Inc. operates as a biotechnology company. The Company develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. ... 1-617-876-8191 ...


PDF GENOCEA BIOSCIENCES, INC. - files.shareholder.com

(617) 876-8191 (Address, including zip code, and telephone number, including area code, of registrant's principal exe cutive office) William D. Clark President and Chief Executive Officer Genocea Biosciences, Inc. 100 Acorn Park Drive Cambridge, Massachusetts 02140 (617) 876-8191


Genocea Biosciences, Inc. 8-K Sep. 27, 2017 8:56 AM | Seeking ...

(Registrant's telephone number, including area code): (617) 876-8191 Not Applicable ... On September 27, 2017, Genocea Biosciences, Inc. updated its corporate presentation. A copy of the ...


GNCA: Genocea Biosciences, Inc. - Zacks Investment Research

Get the latest Full Company Report for Genocea Biosciences, Inc. from Zacks Investment Research Join ... 617-876-8191 . Fax: 617-876-8192 .


Press Releases — Investor Relations — Genocea Biosciences

First immunogenicity data now expected in mid-2019 CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the dosing of the first patients in its Phase 1/2a clinical